Koen Sandra Joins LCGC’s Editorial Advisory Board
LCGC is pleased to announce the addition of Koen Sandra to its editorial advisory board.
Sandra received his PhD in Biochemistry from Ghent University in Belgium in 2005. He then joined Pronata, a molecular diagnostic company, where he was active in developing analytical platforms for disease biomarker discovery and in setting up external collaborations.
In 2008, Sandra joined the Research Institute for Chromatography, where he focuses on life sciences. Currently, he leads a team of scientists working on all aspects of life sciences, including (bio)pharmaceutical analysis, proteomics, metabolomics, and lipidomics. Additionally, he serves as a consultant for several (bio)pharmaceutical and biotech companies and instrument manufacturers.
As a non-academic scientist, Sandra is the author of more than 30 highly-cited scientific papers, and has presented his work at numerous conferences as an invited speaker. He holds several patents related to analytical developments in the life sciences.
Presenting GC Data Comparisons to Laypersons to Understand Potential Courtroom Implications
January 6th 2025In forensic science, scientific testimony is routinely presented in court to juries who may have limited or no scientific background, putting law enforcement and defense personnel in the position of having to make rapid decisions in short timeframes based on findings of which they are not specialists. Katelynn Perrault Uptmor, Assistant Professor of Chemistry at William & Mary (Williamsburg, Virginia) believes that the introduction of new technologies into the framework of routine forensic analysis must therefore bridge the gap between introduction of new and novel analytical science and the communication of that science to a court of law, and that analytical chemistry research must be mindful of the need to fill this gap in promoting new technologies.
Detailed Glycosylation Analysis of Therapeutic Enzymes Utilizing Comprehensive 2D-LC–MS
January 3rd 2025In this article, the use of comprehensive two-dimensional liquid chromatography (LC×LC) coupled to mass spectrometry (MS) for characterizing glycosylation of therapeutic enzymes is presented.
Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this progress builds, the industry remains accountable for characterizing these molecules to meet the requirements of regulatory authorities.
